Synthesis of oxamide-hydrazone hybrid derivatives as potential anticancer agents.

IF 2.1 Q3 CHEMISTRY, MEDICINAL
Mina Dehbid, Raheleh Tahmasvand, Marzieh Tasharofi, Fatemeh Shojaie, Mahmoudreza Aghamaali, Ali Almasirad, Mona Salimi
{"title":"Synthesis of oxamide-hydrazone hybrid derivatives as potential anticancer agents.","authors":"Mina Dehbid,&nbsp;Raheleh Tahmasvand,&nbsp;Marzieh Tasharofi,&nbsp;Fatemeh Shojaie,&nbsp;Mahmoudreza Aghamaali,&nbsp;Ali Almasirad,&nbsp;Mona Salimi","doi":"10.4103/1735-5362.363593","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and purpose: </strong>Considering various studies implying anticancer activity of the hydrazone and oxamide derivatives through different mechanisms such as kinases and calpain inhibition, herein, we report the synthesis, characterization, and evaluation of the antiproliferative effect of a series of hydrazones bearing oxamide moiety compounds (<b>7a-7n</b>) against a panel of cancer cell lines to explore a novel and promising anticancer agent (<b>7k</b>).</p><p><strong>Experimental approach: </strong>Chemical structures of the synthesized compounds were confirmed by FTIR, <sup>1</sup>H-NMR, <sup>13</sup>C-NMR, and mass spectra. The antiproliferative activity and cell cycle progression of the target compound were investigated using the MTT assay and flow cytometry.</p><p><strong>Findings/results: </strong>Compound <b>7k</b> with 2-hydroxybenzylidene structure was found to have a significant <i>in vitro</i> anti-proliferative influence on MDA-MB-231 (human adenocarcinoma breast cancer) and 4T1 (mouse mammary tumor) cells as the model of triple-negative breast cancer, with the IC50-72h values of 7.73 ± 1.05 and 1.82 ± 1.14 μM, respectively. Following 72-h incubation with compound <b>7k</b>, it caused MDA-MB-231 cell death through G1/S cell cycle arrest at high concentrations (12 and 16 μM).</p><p><strong>Conclusion and implications: </strong>Conclusively, this study for the first time reports the anti-proliferative efficacy of compound <b>7k</b> possessing 2-hydroxyphenyl moiety, which may serve as a potent candidate in triple-negative breast cancer treatment.</p>","PeriodicalId":21075,"journal":{"name":"Research in Pharmaceutical Sciences","volume":"18 1","pages":"24-38"},"PeriodicalIF":2.1000,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/df/49/RPS-18-24.PMC9951783.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Research in Pharmaceutical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/1735-5362.363593","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background and purpose: Considering various studies implying anticancer activity of the hydrazone and oxamide derivatives through different mechanisms such as kinases and calpain inhibition, herein, we report the synthesis, characterization, and evaluation of the antiproliferative effect of a series of hydrazones bearing oxamide moiety compounds (7a-7n) against a panel of cancer cell lines to explore a novel and promising anticancer agent (7k).

Experimental approach: Chemical structures of the synthesized compounds were confirmed by FTIR, 1H-NMR, 13C-NMR, and mass spectra. The antiproliferative activity and cell cycle progression of the target compound were investigated using the MTT assay and flow cytometry.

Findings/results: Compound 7k with 2-hydroxybenzylidene structure was found to have a significant in vitro anti-proliferative influence on MDA-MB-231 (human adenocarcinoma breast cancer) and 4T1 (mouse mammary tumor) cells as the model of triple-negative breast cancer, with the IC50-72h values of 7.73 ± 1.05 and 1.82 ± 1.14 μM, respectively. Following 72-h incubation with compound 7k, it caused MDA-MB-231 cell death through G1/S cell cycle arrest at high concentrations (12 and 16 μM).

Conclusion and implications: Conclusively, this study for the first time reports the anti-proliferative efficacy of compound 7k possessing 2-hydroxyphenyl moiety, which may serve as a potent candidate in triple-negative breast cancer treatment.

Abstract Image

Abstract Image

Abstract Image

作为潜在抗癌剂的氧酰胺-腙杂化衍生物的合成。
背景和目的:考虑到各种研究表明,腙和草酰胺衍生物通过不同的机制(如激酶和钙蛋白酶抑制)具有抗癌活性,在此,我们报道了一系列含草酰胺部分化合物(7a-7n)的腙对一系列癌细胞系的抗增殖作用的合成、表征和评价,以探索一种新的有前途的抗癌药物(7k)。实验方法:合成化合物的化学结构通过FTIR、1H-NMR、13C-NMR和质谱进行确证。采用MTT法和流式细胞术研究目标化合物的抗增殖活性和细胞周期进展。结果:2-羟基苄基结构化合物7k对三阴性乳腺癌模型MDA-MB-231(人腺癌乳腺癌)和4T1(小鼠乳腺肿瘤)细胞具有显著的体外抗增殖作用,IC50-72h值分别为7.73±1.05和1.82±1.14 μM。化合物7k孵育72 h后,高浓度(12 μM和16 μM)使MDA-MB-231细胞G1/S周期阻滞,导致细胞死亡。结论和意义:本研究首次报道了含有2-羟基苯基片段的化合物7k的抗增殖作用,可能是治疗三阴性乳腺癌的有力候选药物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Research in Pharmaceutical Sciences
Research in Pharmaceutical Sciences CHEMISTRY, MEDICINAL-
CiteScore
3.60
自引率
19.00%
发文量
50
审稿时长
34 weeks
期刊介绍: Research in Pharmaceutical Sciences (RPS) is included in Thomson Reuters ESCI Web of Science (searchable at WoS master journal list), indexed with PubMed and PubMed Central and abstracted in the Elsevier Bibliographic Databases. Databases include Scopus, EMBASE, EMCare, EMBiology and Elsevier BIOBASE. It is also indexed in several specialized databases including Scientific Information Database (SID), Google Scholar, Iran Medex, Magiran, Index Copernicus (IC) and Islamic World Science Citation Center (ISC).
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信